Blueprint Medicines Corporation Stock News

Blueprint Medicines Corporation (NASDAQ: BPMC ) and Proteovant Therapeutics have entered a strategic collaboration for targeted protein degrader therapies . The collaboration will bring Proteovant''s Artificial Intelligence (AI)-enhanced targeted protein degradation (TPD) platform and Blueprint Medicine''s precision medicine expertise to discover novel targeted protein degraders. The companies will … Full story available on Benzinga.com

Blueprint Medicines (BPMC) and Proteovant Therapeutics will collaborate on protein degrader therapies and advance up to two candidates into development.The collaboration will…

Blueprint Medicines Corporation (NASDAQ: BPMC) and Proteovant Therapeutics today announced a strategic collaboration to advance novel targeted protein degrader therapies to address important areas of medical need. Targeted protein degradation harnesses the body''s natural protein disposal system and offers the potential to develop new medicines that target historically difficult-to-drug proteins that play an important role in causing serious diseases.

Blueprint Medicines (BPMC) misses on earnings while revenue beat estimates for the fourth quarter of 2021. Stock down.

Shares of Blueprint Medicines (BPMC) are down in morning trading after at least two Street firms weighed in on the company Q4 2021 results released Wednesday.

Over the past 3 months, 5 analysts have published their opinion on Blueprint Medicines (NASDAQ:BPMC) stock. These analysts are typically employed by large Wall Street banks and tasked with understandi

Over the past 3 months, 5 analysts have published their opinion on Blueprint Medicines (NASDAQ: BPMC ) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company''s business to predict how a stock will trade over the upcoming year. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 1 2 0 0 Last 30D 1 0 1 0 0 1M Ago 1 0 1 0 0 2M Ago 0 1 0 0 0 3M Ago 0 0 0 0 0 In the last 3 months, 5 analysts have offered 12-month price targets for Blueprint Medicines. The company has an average price target of $97.8 with a high of $120.00 and a low of $82.00. Below is a summary of … Full story available on Benzinga.com

Blueprint Medicines (BPMC) misses on earnings while revenue beat estimates for the fourth quarter of 2021. Stock down.

Blueprint Medicines <> is trading sharply lower in the morning hours on Wednesday after the company initiated a lower-than-expected revenue guidance for 2022

Shares of Blueprint Medicines Corporation (BPMC) are falling more than 9% Wednesday morning after the company reported wider loss for the fourth-quarter that missed the Street view. The company''s full-year revenue outlook also came in below consensus estimates.

Blueprint Medicines' (BPMC) CEO Jeff Albers on Q4 2021 Results - Earnings Call Transcript

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -39.44% and 3.17%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hookipa Gets $15M Upfront Payment And Equity Investment From Gilead Following Amended HIV Study Agreem

Blueprint Medicines press release (BPMC): Q4 GAAP EPS of -$5.40 misses by $4.25.Revenue of $107M (+213.7% Y/Y) beats by $2.86M.Blueprint Medicines today announced it…